Creatinine Clearance Calculator (Cockcroft-Gault)
Estimate creatinine clearance for drug dosing using the Cockcroft-Gault equation. Calculates CrCl with actual, ideal, and adjusted body weight — the standard method referenced by most drug prescribing labels.
Calculate Creatinine Clearance
Enter patient demographics and serum creatinine. The calculator provides CrCl using actual body weight (ABW), ideal body weight (IBW), and adjusted body weight (AdjBW). Height is required for IBW and AdjBW calculations — for drug dosing in obese patients (ABW > 120% IBW), use the AdjBW-based CrCl.
The Cockcroft-Gault equation estimates creatinine clearance, not GFR. CrCl overestimates true GFR by approximately 10–15% due to tubular creatinine secretion. This calculator is specifically intended for drug dosing, as most pharmaceutical labelling and pharmacokinetic studies reference Cockcroft-Gault. For CKD staging and prognosis, use the CKD-EPI eGFR calculator instead.
Understanding Creatinine Clearance
Creatinine clearance (CrCl) is a measure of renal function that approximates the rate at which the kidneys filter creatinine from the blood. Creatinine is a byproduct of skeletal muscle creatine metabolism and is produced at a relatively constant rate, freely filtered by the glomerulus, and secreted (but not reabsorbed) by the proximal tubule. Because of this tubular secretion, CrCl slightly overestimates true GFR.
The Cockcroft-Gault equation was published in 1976 by Donald Cockcroft and Henry Gault. It was derived from a cohort of 249 hospitalised males aged 18–92, using 24-hour urine creatinine clearance as the reference. Despite being over four decades old and predating modern creatinine assay standardisation (IDMS), it remains the most widely referenced equation for renal dose adjustment in drug prescribing information worldwide.
Cockcroft-Gault Formula
CrCl = [(140 − Age) × Weight] / (72 × SCr)
× 0.85 if female
Age in years, weight in kg, SCr in mg/dL. Result in mL/min. The 0.85 correction for females accounts for the approximately 15% lower creatinine production from lower average muscle mass.
Worked Example
65-year-old female, 70 kg, SCr = 1.2 mg/dL
CrCl = [(140 − 65) × 70] / (72 × 1.2) × 0.85
= [75 × 70] / 86.4 × 0.85
= 5250 / 86.4 × 0.85
= 60.76 × 0.85 = 51.6 mL/min
Ideal Body Weight (IBW)
Males: 50 + 2.3 × (height in inches − 60)
Females: 45.5 + 2.3 × (height in inches − 60)
IBW (Devine formula) estimates lean body mass based on height and sex. Used as the weight input in CG for patients at or below their ideal weight.
Adjusted Body Weight (AdjBW)
AdjBW = IBW + 0.4 × (ABW − IBW)
AdjBW accounts for the fact that adipose tissue contributes some (but not proportional) creatinine clearance. The 0.4 correction factor is the most widely used, though evidence for the optimal factor is limited. Recommended when ABW exceeds 120% of IBW.
CrCl vs. eGFR — when to use which: Use Cockcroft-Gault CrCl for drug dosing — most pharmaceutical labelling, FDA approvals, and pharmacokinetic dose-adjustment tables are based on CG. Use CKD-EPI eGFR for CKD staging, prognosis, and referral decisions. These are different numbers answering different clinical questions, and they should not be used interchangeably.
Drug Dosing Tiers & Renal Adjustment Thresholds
Most renally cleared medications use standardised CrCl thresholds for dose adjustment. The table below shows the most common thresholds referenced in prescribing information. Always verify against the specific drug’s current product label, as thresholds vary by medication.
| CrCl (mL/min) | Category | Typical Drug Dosing Action | Common Examples |
|---|---|---|---|
| ≥ 80 | Normal / near-normal | Standard dosing — no adjustment needed | Most drugs at full dose |
| 50–79 | Mild impairment | Dose reduction or interval extension for selected drugs | Gabapentin, pregabalin, DOACs (some), tenofovir |
| 30–49 | Moderate impairment | Dose reduction required for many renally cleared drugs | Metformin (reduce dose), enoxaparin, dabigatran, rivaroxaban |
| 15–29 | Severe impairment | Major dose reduction or avoidance; close monitoring needed | Metformin (contraindicated by some labels), most DOACs (caution/avoid) |
| < 15 | End-stage / dialysis | Drug-specific guidance; many require post-dialysis supplementation | Vancomycin (per levels), aminoglycosides (per levels), many drugs contraindicated |
The thresholds above are generalisations. Some drugs use different breakpoints (e.g., edoxaban uses CrCl > 95, where higher clearance reduces efficacy). Others use continuous dose-proportional scaling (e.g., aminoglycosides dosed per AUC). Always check the specific drug’s prescribing information — never rely solely on generic CrCl-tier tables for critical medications.
Which Weight to Use in Cockcroft-Gault
The choice of body weight in the Cockcroft-Gault equation is one of the most debated aspects of renal dose adjustment. The original equation used actual body weight, but this was derived from a predominantly non-obese hospitalised male population. In clinical practice, different weight inputs are appropriate for different body compositions.
For patients whose actual weight is within 20% of their ideal body weight, use ABW in the Cockcroft-Gault equation. This is the weight used in the original derivation study and reflects the total creatinine-producing mass, which correlates with both muscle and overall body size in non-obese individuals.
ABW is also appropriate for underweight patients whose ABW falls below their calculated IBW. In this scenario, using IBW would overestimate CrCl — the lower muscle mass of an underweight patient produces less creatinine, and ABW more accurately reflects their actual clearance capacity.
IBW (Devine 1974) estimates the weight of lean tissue based on height and sex. Some pharmacists and guidelines recommend IBW in the CG equation for all patients, arguing that creatinine production is proportional to lean mass rather than total body weight. However, this approach systematically underestimates CrCl in obese patients because adipose tissue does contribute some blood flow and creatinine clearance.
IBW is most useful as a reference point: if ABW < IBW, use ABW (the patient has less lean mass than predicted). If ABW > 120% of IBW, the patient is considered obese for pharmacokinetic purposes, and adjusted body weight should be used.
When ABW exceeds 120% of IBW, using ABW in CG overestimates CrCl (adipose tissue does not produce creatinine proportionally), while using IBW underestimates it (adipose tissue does contribute some renal blood flow and clearance). The adjusted body weight formula — AdjBW = IBW + 0.4 × (ABW − IBW) — is a pragmatic compromise widely recommended by clinical pharmacology references and the ASHP.
The 0.4 correction factor is conventional but not firmly evidence-based. Some studies suggest 0.3–0.5 may be more appropriate for specific drugs. In clinical practice, when in doubt for obese patients, the AdjBW-based CrCl provides the most balanced estimate and is the safest choice for dose adjustment of narrow-therapeutic-index drugs.
ABW < IBW: Use ABW (underweight — IBW would overestimate).
ABW within 80–120% of IBW: Use ABW (standard patient — original CG derivation).
ABW > 120% of IBW: Use AdjBW (obese — ABW would overestimate, IBW would underestimate).
Special Populations & Considerations
Creatinine assay matters: The original CG equation was derived using older (non-IDMS-standardised) creatinine assays, which measured approximately 0.1–0.2 mg/dL higher than modern IDMS-traceable methods. Modern lower creatinine values may yield higher CG estimates than the original study intended. Some authors suggest adding 0.2 mg/dL to IDMS-standardised creatinine before using CG, though this practice is not universal.
Stepwise Renal Dose Adjustment Approach
A systematic approach to renal dose adjustment reduces prescribing errors and ensures that both efficacy and safety are maintained. The following steps should be applied whenever prescribing a renally cleared medication.
Not all drugs require renal dose adjustment. Check whether the drug or its active metabolites are significantly renally eliminated (> 30% renal excretion). Good resources include the manufacturer’s prescribing information (SmPC/PI), the Renal Drug Handbook (Ashley & Dunleavy), and pharmacy databases. Drugs that are primarily hepatically metabolised (e.g., warfarin, most statins, amlodipine) typically do not need renal dose changes.
Calculate CrCl using Cockcroft-Gault with the appropriate weight: ABW for normal-weight and underweight patients, AdjBW for obese patients (ABW > 120% IBW). Ensure you are using a current serum creatinine at steady state (not during AKI). Note the CrCl unit is mL/min — not normalised to body surface area (unlike eGFR, which is mL/min/1.73 m²).
Cross-reference the calculated CrCl with the drug’s renal dosing table. Common adjustments include: dose reduction (e.g., halving the dose), interval extension (e.g., from q12h to q24h), or both. For drugs with narrow therapeutic indices (vancomycin, aminoglycosides, digoxin), use CrCl as a starting point for initial dosing, then titrate based on therapeutic drug monitoring (TDM).
Be cautious at CrCl boundaries — if CrCl is near a threshold (e.g., 31 vs. 29 mL/min), consider the patient’s trajectory, clinical context, and whether the creatinine is stable. A CrCl of 31 in a patient whose creatinine is rising may soon fall below 30.
Renal function is dynamic. Reassess CrCl when: creatinine changes by > 20%, clinical status changes (sepsis, dehydration, new nephrotoxin), or at regular intervals for ongoing therapy. For narrow-therapeutic-index drugs, use TDM to confirm adequate dosing rather than relying solely on CrCl-based estimates. Document the CrCl used, the weight input chosen, and the rationale for dose adjustments.
Common Pitfalls & Limitations
CKD-EPI eGFR and Cockcroft-Gault CrCl are not interchangeable for drug dosing. eGFR is reported in mL/min/1.73 m² (normalised to body surface area), while CG produces CrCl in mL/min (absolute, not normalised). The values can diverge significantly — especially in patients who are very large, very small, very old, or very muscular. Most drug labels were developed using CG-based CrCl, and using eGFR instead can lead to under- or over-dosing. Some drugs (notably DOACs) have been studied with both, but unless the prescribing information explicitly states eGFR is acceptable, use CG.
Plugging actual body weight into CG for an obese patient produces an inflated CrCl that does not reflect true renal clearance. A 150 kg patient does not have proportionally more kidney function than a 75 kg patient of the same height. This can result in dangerous overdosing of renally cleared drugs — particularly nephrotoxic antibiotics, anticoagulants, and chemotherapy agents. Always calculate IBW, compare it to ABW, and use AdjBW when ABW exceeds 120% of IBW.
A frail 85-year-old with a serum creatinine of 0.6 mg/dL may appear to have a reasonable CrCl by CG calculation. However, the low creatinine reflects low muscle mass and minimal creatinine production — not excellent kidney function. In reality, their true GFR may be significantly lower. This pitfall is especially dangerous with drugs like digoxin, lithium, and DOACs where accumulation causes serious toxicity. Clinical vigilance, lower initial dosing, and early TDM are appropriate in this population.
The CG equation assumes a steady-state serum creatinine. During AKI, creatinine is actively rising and has not yet equilibrated with the degree of kidney dysfunction. A patient whose creatinine has risen from 1.0 to 2.0 mg/dL over 24 hours has a much lower true clearance than the CG-based CrCl calculated using the current value of 2.0. Using CG in AKI leads to systematic overestimation of clearance and potentially dangerous overdosing. In AKI, use empirical dose reduction, pharmacist consultation, and TDM.
Modern IDMS-standardised creatinine assays produce values approximately 0.1–0.2 mg/dL lower than the older Jaffe-based assays used in the original CG derivation. This means CG calculated with modern creatinine values may yield CrCl estimates that are 10–20% higher than the original study intended, particularly at lower creatinine levels. While most institutions do not routinely correct for this, awareness of the issue is important — especially when CrCl falls near a dosing threshold and even small differences could change the dose tier.
Quick Reference Summary
published
factor
for obesity adjustment
for AdjBW
| Patient Type | Weight to Use | Rationale |
|---|---|---|
| Normal weight (ABW within 80–120% IBW) | ABW | Original CG derivation; reflects true creatinine-producing mass |
| Underweight (ABW < IBW) | ABW | Less muscle mass than predicted — IBW would overestimate CrCl |
| Obese (ABW > 120% IBW) | AdjBW | ABW overestimates; IBW underestimates; AdjBW = IBW + 0.4 × (ABW − IBW) |
| Morbidly obese (BMI > 40) | AdjBW + TDM | AdjBW as starting estimate; confirm with drug levels for narrow-TI drugs |
The Golden Rule: Cockcroft-Gault is for drug dosing; CKD-EPI is for CKD staging. They answer different questions, use different units, and should not be used interchangeably. When CrCl falls near a dose-adjustment threshold, check the drug label, consider the patient trajectory, and use therapeutic drug monitoring for high-risk medications.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. DOI: 10.1159/000180580
- Devine BJ. Gentamicin therapy. Drug Intelligence & Clinical Pharmacy. 1974;8(11):650-655. DOI: 10.1177/106002807400801104
- Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604-612. DOI: 10.1002/j.1875-9114.2012.01098.x
- Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing. Pharmacotherapy. 2011;31(11):1130-1144. DOI: 10.1592/phco.31.11.1130
- Hudson JQ, Nolin TD. Pragmatic use of kidney function estimates for drug dosing: the tide is turning. Advances in Chronic Kidney Disease. 2018;25(1):14-20. DOI: 10.1053/j.ackd.2017.10.003
- Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Advances in Chronic Kidney Disease. 2010;17(5):e53-e62. DOI: 10.1053/j.ackd.2010.05.010
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2024;105(4S):S117-S314. DOI: 10.1016/j.kint.2023.10.018
- Spruill WJ, Wade WE, Cobb HH. Estimating glomerular filtration rate with a modification of diet in renal disease equation: implications for pharmacy. American Journal of Health-System Pharmacy. 2009;66(2):154-159. DOI: 10.2146/ajhp080055
- Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA. Measured and estimated glomerular filtration rate: current status and future directions. Nature Reviews Nephrology. 2020;16(1):51-64. DOI: 10.1038/s41581-019-0191-y
- Dowling TC, Matzke GR, Murphy JE, Burckart GJ. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy. 2010;30(8):776-786. DOI: 10.1592/phco.30.8.776